SCHEMBL1755281

SCHEMBL1755281

Bc1cc2c(NC3CCC3)ncnc2cc1OCc1cccc(S(C)(=O)=NC(=O)OCC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.39
EGFR P00533 6/20 0.36
USP2 O75604 2/20 0.36
CYP1A2 P05177 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
LMNA P02545 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
CNR1 P21554 3/20 0.36
CNR2 P34972 3/20 0.36
IRAK4 Q9NWZ3 4/20 0.35
ERBB2 P04626 4/20 0.35
ERBB4 Q15303 2/20 0.35
MAP4K4 O95819 1/20 0.35
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.34
PIK3CD O00329 2/20 0.34
MAPT P10636 1/20 0.33
NR2F2 P24468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707273 0.91 NSD2 (0.39) NSD2EGFRUSP2CYP1A2CLK4
SCHEMBL1706781 0.91 NSD2 (0.47) NSD2EGFRMAPK1IRAK4HTT
SCHEMBL1755282 0.88 EGFR (0.36) EGFRLMNAMAPK1ERBB2ERBB4
SCHEMBL1708497 0.88 NSD2 (0.49) NSD2EGFRUSP2CYP1A2CLK4
SCHEMBL1706605 0.88 NSD2 (0.40) NSD2EGFRUSP2CYP1A2CLK4
SCHEMBL13536785 0.86 NSD2 (0.45) NSD2EGFRUSP2CYP1A2CLK4
SCHEMBL13784501 0.85 MAPK1 (0.37) EGFRLMNAMAPK1ERBB2ERBB4
SCHEMBL1755318 0.84 KDR (0.37) EGFRLMNAMAPK1ERBB2ERBB4
SCHEMBL1707495 0.84 NSD2 (0.47) NSD2EGFRMAPK1IRAK4HTT
SCHEMBL1706486 0.80 NSD2 (0.49) NSD2EGFRUSP2CYP1A2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247579-B1 SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS Bayer Pharma AG (DE) 2012-04-18 EP disclosed